NASDAQ: AMTI - Applied Molecular Transport Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Applied Molecular Transport Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc., биофармацевтическая компания, работающая на клинической стадии, участвует в разработке линейки пероральных биологических продуктов-кандидатов для лечения аутоиммунных, воспалительных, метаболических и других заболеваний. Ведущим кандидатом на продукцию является AMT-101, селективный интерлейкин 10 для перорального применения в желудочно-кишечном тракте (ЖКТ), который прошел клинические испытания фазы 1b у пациентов с язвенным колитом (ЯК).

more details
Компания с помощью своей технологической платформы проектирует и разрабатывает различные пероральные биологические терапевтические средства, такие как пептиды, белки, антитела, фрагменты антител и РНК-препараты. Кроме того, он участвует в разработке AMT-126, GI-селективного перорального слияния rhIL-22 для лечения заболеваний, связанных с дефектами барьерной функции кишечного эпителия. Applied Molecular Transport Inc. была основана в 2010 году со штаб-квартирой в Южном Сан-Франциско, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-06-05
ISIN US03824M1099
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.appliedmt.com
Цена ао 0.263
Change price per day: 0% (0.263)
Change price per week: 0% (0.263)
Change price per month: 0% (0.263)
Change price per 3 month: 0% (0.263)
Change price per half year: 0% (0.263)
Change price per year: 0% (0.263)
Change price per 3 year: -96.08% (6.705)
Change price per 5 year: 0% (0.263)
Change price per 10 year: 0% (0.263)
Change price per year to date: 0% (0.263)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.2385 10
P/E 0 0
EV/EBITDA 0.0826 10
Total: 5

Efficiency

Title Value Grade
ROA, % -78.03 0
ROE, % -111.78 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2838 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 243.48 10
Yield EPS, % 115.38 10
Total: 8
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
01.09.2022 06.09.2022 Cross Shawn
President & COO		 Sale 1.42 1 255 884 0 0 link
01.09.2022 06.09.2022 Hants Brandon
CFO		 Sale 1.42 656 462 0 0 link
01.09.2022 06.09.2022 Kanwar Bittoo
Chief Medical Officer		 Sale 1.42 714 503 0 0 link
01.09.2022 06.09.2022 Mahmood Tahir Ph.D.
Chief Executive Officer		 Sale 1.42 2 447 1723 0 0 link
01.09.2022 06.09.2022 Mrsny Randall Ph.D.
Director		 Sale 1.42 574 404 0 0 link
01.09.2022 06.09.2022 Rich Douglas A.
Chief Technical Officer		 Sale 1.42 636 448 0 0 link
02.06.2022 03.06.2022 Cross Shawn
President & COO		 Sale 3.04 6 585 2166 0 -0.01 link
02.06.2022 03.06.2022 Hants Brandon
CFO		 Sale 3.04 3 411 1122 0 0 link
02.06.2022 03.06.2022 Kanwar Bittoo
Chief Medical Officer		 Sale 3.04 6 676 2196 0 -0.01 link
02.06.2022 03.06.2022 Mahmood Tahir Ph.D.
Chief Executive Officer		 Sale 3.04 5 147 1693 0 0 link
02.06.2022 03.06.2022 Mrsny Randall Ph.D.
Director		 Sale 3.04 1 192 392 0 0 link
01.06.2022 03.06.2022 Cross Shawn
President & COO		 Sale 2.97 5 248 1767 0 0 link
01.06.2022 03.06.2022 Hants Brandon
CFO		 Sale 2.97 2 718 915 0 0 link
01.06.2022 03.06.2022 Kanwar Bittoo
Chief Medical Officer		 Sale 2.97 5 322 1792 0 0 link
01.06.2022 03.06.2022 Mahmood Tahir Ph.D.
Chief Executive Officer		 Sale 2.97 4 105 1382 0 0 link
01.06.2022 03.06.2022 Mrsny Randall Ph.D.
Director		 Sale 2.97 947 319 0 0 link

Institutions Volume Share, %
EPIQ Capital Group, LLC 8689075 21.02
Founders Fund V Management, LLC 3611615 8.74
Vanguard Group Inc 866392 2.1
Founders Fund VI Management, LLC 826607 2
Blackrock Inc. 456409 1.1
Renaissance Technologies, LLC 282187 0.68
Laurion Capital Management, LP 217828 0.53
Geode Capital Management, LLC 139808 0.34
HRT Financial LP 113307 0.27
Wealth Enhancement Advisory Services, LLC 66207 0.16



Head Job title Payment Year of birth
Mr. Shawn M. Cross Pres & COO 679.78k 1968 (57 years)
Mr. Brandon Hants Chief Financial Officer 469.67k 1977 (48 years)
Mr. Andrew H. Chang Head of Investor Relations & Corp. Communications N/A
Dr. Tahir Mahmood Ph.D. Co-Founder, CEO & Director 870.29k 1975 (50 years)
Mr. Graham K. Cooper Exec. Chairman 1970 (55 years)
Dr. Randall Mrsny Ph.D. Co-Founder & Director 1955 (70 years)
Dr. Bittoo Kanwar M.D. Chief Medical Officer 1976 (49 years)
Mr. Douglas A. Rich M.B.A, M.B.A. Chief Technical Officer 1969 (56 years)
Mr. Earl M. Douglas Exec. VP & Gen. Counsel 1963 (62 years)
Dr. Andy Whitney Ph.D. Sr. VP of Research & Translational Science 1961 (64 years)

Address: United States, South San Francisco, CA , 1 Tower Place - open in Google maps, open in Yandex maps
Website: https://www.appliedmt.com